Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Overactive bladder (OAB) is a bothered symptom syndrome. Traditional medication for OAB is
antimuscarinic agent. However, adverse events such as dry mouth, constipation, blurred
vision, and dizziness may prohibit patient to take this drug for OAB. Intravesical botulinum
toxin A (BoNT-A) is a novel treatment however, BoNT-A can cause acute urinary retention and
large postvoid residual. In this grant we will evaluate liquid liposome delivery of BoNT-A
(Liposome encapsulated BoNT-A) into the bladder without the need for cystoscopic-guided
needle injection for refractory OAB.
Phase:
Phase 2
Details
Lead Sponsor:
Buddhist Tzu Chi General Hospital
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA